比美吉珠单抗治疗中轴型脊柱关节炎患者葡萄膜炎发生率低:2b/3期试验汇总结果
汇总BE MOBILE 1和2双盲期数据,比美吉珠单抗组葡萄膜炎发生率0.6%(2/349)vs 安慰剂组4.6%(11/237),名义p=0.001;暴露校正发生率分别为1.8/100患者年 vs 15.4/100患者年。2b/3期汇总池(N=848)暴露校正发生率维持低水平1.2/100患者年。
要点
- 双盲期比美吉珠单抗组葡萄膜炎发生率0.6%(2/349),安慰剂组4.6%(11/237),名义p=0.001。
- 有葡萄膜炎病史者中,比美吉珠单抗组暴露校正发生率6.2/100患者年 vs 安慰剂组70.4/100患者年,名义p=0.004。
- 2b/3期汇总池(N=848,暴露2034.4患者年)暴露校正发生率1.2/100患者年(95%CI 0.8至1.8)。
核心结论
- 比美吉珠单抗作为一种双重IL-17A/F抑制剂,可能对中轴型脊柱关节炎患者的葡萄膜炎具有保护作用。
研究设计与样本
- 汇总BE MOBILE 1(NCT03928704,非放射学中轴型脊柱关节炎)和BE MOBILE 2(NCT03928743,放射学中轴型脊柱关节炎)3期试验双盲治疗期接受比美吉珠单抗160 mg或安慰剂的患者数据。
- 另单独汇总BE MOBILE试验及其正在进行的开放标签延伸研究(OLE;NCT04436640)中至少接受一剂比美吉珠单抗的患者,以及2b期BE AGILE试验(NCT02963506,放射学中轴型脊柱关节炎)及其正在进行的OLE(NCT03355573)中的数据。
- 报告葡萄膜炎发生率和暴露校正发生率(EAIR)/100患者年(PYs)。
主要发现
- BE MOBILE 1和2双盲治疗期,比美吉珠单抗组0.6%(2/349)患者发生葡萄膜炎,安慰剂组4.6%(11/237),名义p=0.001;EAIR(95%CI)分别为1.8/100 PYs(0.2至6.7) vs 15.4/100 PYs(95%CI 7.7至27.5)。
- 有葡萄膜炎病史的患者中,比美吉珠单抗组EAIR为6.2/100 PYs(95%CI 0.2至34.8),发生率1.9%;安慰剂组EAIR为70.4/100 PYs(95%CI 32.2至133.7),发生率20.0%;名义p=0.004。
- 2b/3期汇总池(N=848;比美吉珠单抗暴露2034.4 PYs)中EAIR维持低水平,为1.2/100 PYs(95%CI 0.8至1.8)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: Acute anterior uveitis ('uveitis') is a common axial spondyloarthritis (axSpA) extramusculoskeletal manifestation. Interleukin (IL)-17 is implicated in its pathogenesis, however, there is conflicting evidence for IL-17A inhibition in uveitis management. We report pooled analyses of uveitis incidence in patients receiving bimekizumab (BKZ), a monoclonal IgG1 antibody that selectively inhibits IL-17F in addition to IL-17A, from phase 2b/3 trials. METHODS: Data were pooled for patients receiving BKZ 160 mg or placebo in the double-blind treatment period of the phase 3 BE MOBILE 1 (NCT03928704; non-radiographic axSpA) and BE MOBILE 2 (NCT03928743; radiographic axSpA) trials. Data were separately pooled for patients treated with at least one BKZ dose in the BE MOBILE trials and their ongoing open-label extension (OLE; NCT04436640), and the phase 2b BE AGILE trial (NCT02963506; radiographic axSpA) and its ongoing OLE (NCT03355573). Uveitis rates and exposure-adjusted incidence rates (EAIR)/100 patient-years (PYs) are reported. RESULTS: In the BE MOBILE 1 and 2 double-blind treatment period, 0.6% (2/349) of patients receiving BKZ experienced uveitis vs 4.6% (11/237) receiving placebo (nominal p=0.001; EAIR (95% CI): 1.8/100 PYs (0.2 to 6.7) vs 15.4/100 PYs (95% CI 7.7 to 27.5)). In patients with history of uveitis, EAIR was lower in patients receiving BKZ (6.2/100 PYs (95% CI 0.2 to 34.8); 1.9%) vs placebo (70.4/100 PYs (95% CI 32.2 to 133.7); 20.0%; nominal p=0.004). In the phase 2b/3 pool (N=848; BKZ exposure: 2034.4 PYs), EAIR remained low (1.2/100 PYs (95% CI 0.8 to 1.8)). CONCLUSIONS: Bimekizumab, a dual-IL-17A/F inhibitor, may confer protective effects for uveitis in patients with axSpA.
引用
- Brown MA, Rudwaleit M, van Gaalen FA, et al. Low uveitis rates in patients with axial spondyloarthritis treated with bimekizumab: pooled results from phase 2b/3 trials. Ann Rheum Dis. 2024. PMID: 38977276. doi:10.1136/ard-2024-225933
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。